Acute GVHD
9
1
2
4
Key Insights
Highlights
Success Rate
57% trial completion
Clinical Risk Assessment
Based on trial outcomes
High Risk
Score: 77/100
33.3%
3 terminated out of 9 trials
57.1%
-29.4% vs benchmark
11%
1 trials in Phase 3/4
50%
2 of 4 completed with results
Key Signals
Data Visualizations
Phase Distribution
Trial Status
Trial Success Rate
Benchmark: 86.5%
Based on 4 completed trials
Clinical Trials (9)
Prebiotic Galacto-oligosaccharide and Acute GVHD
Dendritic Cells in Patients With Acute or Chronic Skin Graft Versus Host Disease
A Study of Itolizumab in Combination With Corticosteroids for the First-Line Treatment of Acute Graft Versus Host Disease (EQUATOR)
Ruxolitinib and Steroid As First Line Therapy for Acute GVHD
Tacrolimus in Allogeneic Hematopoietic Stem Cell Transplant (HCT)
A Study to Evaluate Steroid-free Treatment for Standard-Risk aGVHD (BMT CTN 1501)
Sirolimus & Mycophenolate Mofetil as GVHD Prophylaxis in Myeloablative, Matched Related Donor HCT
Exploratory Safety Study of ALD518 in Subjects With Steroid-refractory Acute Graft Versus Host Disease (GVHD)
Photochemotherapy and Graft-versus-leukemia in Acute-leukemia